Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Optical Coherence Tomography of Retina, Alzheimer Disease
Interventions: retinal imaging with low-cost OCT-a/LCI device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Proliferative Diabetic Retinopathy
Interventions: emixustat hydrochloride, Placebo; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Retinopathy of Prematurity, ROP
Interventions: iROP DL; Device
Lead sponsor: Siloam Vision; Industry
Eligibility: 4 Weeks to 2 Years
Enrollment: 1,284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Retinal Disease
Interventions: Finasteride; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinitis Pigmentosa
Interventions: human retinal progenitor cells, Mock injection; Biological · Other
Lead sponsor: jCyte, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Irvine, California • Los Angeles, California • Boston, Massachusetts

Conditions: Pain
Interventions: Intravitreal injection site; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Aflibercept, Triamcinolone Acetonide, Verteporfin; Drug
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Macular Degeneration
Interventions: VEGF Trap; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more

Conditions: Macular Degeneration
Interventions: Low-Intensity Laser Treatment; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 24
States / cities: Mesa, Arizona • Peoria, Arizona • San Francisco, California + 20 more

Conditions: Inherited Retinal Degeneration Associated With RPGR Mutations, Inherited Retinal Degeneration Associated With Biallelic RPE65 Mutations
Interventions: Not listed
Lead sponsor: University College, London; Other
Eligibility: Up to 50 Years
Enrollment: 4,887 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Interventions: Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA); Drug · Other · Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV, Choroidal Neovascularization
Interventions: Combretastatin A-4 Phosphate; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Degeneration
Interventions: Not listed
Lead sponsor: Scott Raymond; Other
Eligibility: 50 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Usher Syndrome, Retinitis Pigmentosa
Interventions: SAR421869; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Usher Syndrome, Cochlear Implantation
Interventions: Experimental manipulation of stimulation parameters; Other
Lead sponsor: Ohio State University; Other
Eligibility: 1 Year to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts • Columbus, Ohio • Nashville, Tennessee

Conditions: Wet Age-related Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 65
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more

Conditions: Age-Related Macular Degeneration
Interventions: Elamipretide; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Choroidal Neovascularization, Macular Degeneration
Interventions: Fluocinolone; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions: Investigational contact OCT system, Investigational noncontact OCT system:; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Retina Center, Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Retinitis Pigmentosa
Interventions: Spin exercise; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypotony Ocular, Cornea Folds and Rupture of Bowman's Membrane Both Eyes, Maculopathy
Interventions: Ophthalmic imaging; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Macular Degeneration
Interventions: Retisert Implant; Drug
Lead sponsor: Control Delivery Systems; Industry
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Diabetic Macular Edema (DME)
Interventions: 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 57
States / cities: Scottsdale, Arizona • Encino, California • Fullerton, California + 50 more

Search by objective public record fields.

Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Automated Screening Device to Detect MTMROP

Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

Intravitreal Injection Site and Perceived Pain

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

Complications of Age-Related Macular Degeneration Prevention Trial

Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and Adolescents

Sildenafil for Treatment of Choroidal Ischemia

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Auditory Neural Function in Implanted Patients With Usher Syndrome

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Fluocinolone Implant to Treat Macular Degeneration

Optimize Pediatric OCT Imaging

ERG/EOG Study in AMD Patients Treated With Ranibizumab

Exercise and RP (AVAMC and Emory)

Anterior Corneal Striae in Hypotony

A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).